SPI1 and lymphoma: Moreover, immune checkpoint blockade (ICB) using an anti-PD-L1 antibody further enhanced the cytotoxic attack via now de-repressed TTIS cells at their TIS lymphoma targets, while such effect was not seen with TUT cells under ICB, or when PU.1 expression was reduced, indicating a specific adaptive T-cell response component underlying DC-like TIS lymphoma cell killing (Fig. 8g, h).